IP Library › Granted Patent US 11,708,421
Granted Patent B2
US 11,708,421 · App. 16/316,629 · Granted Jul 25, 2023

Modular platform for targeted therapeutics

Inventors: Ranit Kedmi (Tel-Aviv, IL); Nuphar Veiga (Yakum, IL); Itai Benhar (Rehovot, IL); Dan Peer (Kiryat-Ono, IL)
Assignee: Ramot at Tel-Aviv University Ltd.
C07K16/30A61K9/127A61K47/543A61P35/00C07K16/2809C07K16/2812C07K16/2815C07K16/2845C07K16/2866C07K16/2896C07K16/4241C12N15/11C12N15/111C12N2320/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,708,421
App. No.
16/316,629
Granted
Jul 25, 2023
Kind
B2
Abstract

A lipidated secondary antibody is disclosed. Particles comprising same are also disclosed.

Claims (12)

1. An immunoparticle comprising a lipidated secondary antibody comprising a secondary antibody attached via a linker to a lipidated peptide comprising an inner membrane lipidation signal, said lipidated secondary antibody is non-covalently attached to an outer surface of a synthetic lipid-based nanoparticle comprising synthetic lipids via said lipidated peptide, and attached to a primary antibody via an antigen recognition domain of said secondary antibody, wherein said secondary antibody has specificity for said primary antibody.

2. The immunoparticle of claim 1 , wherein said primary antibody is a humanized or human primary antibody.

3. The immunoparticle of claim 1 , wherein said immunoparticle is loaded with a diagnostic or a therapeutic agent.

4. The immunoparticle of claim 1 , wherein said therapeutic agent is a polynucleotide agent.

5. The immunoparticle of claim 1 , wherein said primary antibody and said secondary antibody are of different antibody classes or antibody isotypes.

6. The immunoparticle of claim 1 , wherein said primary antibody and said secondary antibody are selected from the group consisting of IgG1, IgG2 and IgG4.

7. The immunoparticle of claim 1 , wherein said lipid-based nanoparticle comprises a charged external surface.

8. The immunoparticle of claim 1 , wherein said lipid-based nanoparticle comprises cationic lipids.

9. The immunoparticle of claim 1 , wherein said primary antibody comprises an Fc region and said secondary antibody binds said Fc region of said primary antibody.

10. The immunoparticle of claim 4 , wherein said polynucleotide agent is an siRNA.

11. The immunoparticle of claim 1 , wherein said lipidated peptide comprises SEQ ID NO: 13.

12. The immunoparticle of claim 1 , wherein said lipidated peptide consists of SEQ ID NO: 13.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2019
From: KEDMI, RANIT; VEIGA, NUPHAR; BENHAR, ITAI; PEER, DAN
To: RAMOT AT TEL-AVIV UNIVERSITY LTD.
Reel/Frame 048039/0073 →
Continuity (2)
Provisional Application 62363417 · Jul 18, 2016
Related Publication 20190309087A1 · Oct 10, 2019
Cited By (1)
US 12,668,643